The Pharmacological and Chemical Profile of Vorinostat (SAHA): A Comprehensive Review Vorinostat (SAHA)' in Farmakolojik ve Kimyasal Profili: Kapsamlı Bir İnceleme
Fabad Journal of Pharmaceutical Sciences, cilt.51, sa.2, ss.1041-1058, 2026 (Scopus, TRDizin)
- Yayın Türü: Makale / Derleme
- Cilt numarası: 51 Sayı: 2
- Basım Tarihi: 2026
- Doi Numarası: 10.55262/fabadeczacilik.1877769
- Dergi Adı: Fabad Journal of Pharmaceutical Sciences
- Derginin Tarandığı İndeksler: Scopus, EMBASE, TR DİZİN (ULAKBİM), Health Research Premium Collection (ProQuest), Pharma Collection (ProQuest)
- Sayfa Sayıları: ss.1041-1058
- Anahtar Kelimeler: HDAC inhibitor, pharmacokinetics, structure–activity relationships, synthesis, Vorinostat
- Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
- Ankara Üniversitesi Adresli: Evet
Özet
Vorinostat (N-hydroxy-N’-phenyloctanediamide) is an HDAC inhibitor that targets HDAC enzymes. In 2006, the U.S. Food and Drug Administration (FDA) approved vorinostat for use as a third-line treatment in patients with refractory and relapsed cutaneous T-cell lymphoma (CTCL). Vorinostat inhibits HDAC enzymes by chelating the zinc ion located in the catalytic site, leading to the reprogramming of gene expression. This process results in cell cycle arrest, suppression of proliferation, and induction of apoptosis in transformed cells. Current studies continue to investigate its potential applications against various cancer types, HIV, and parasitic infections. This article compiles and summarizes literature data on the synthesis, structure–activity relationships, physicochemical properties, as well as the pharmacological characteristics, mechanism of action, and pharmacokinetic profile of vorinostat.